Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
PHILADELPHIA, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
-
- Collaboration brings together Century’s industry leading iPSC-derived allogeneic cell therapy platform with Bristol Myers Squibb’s expertise in cell therapy and oncology drug development - - First...
-
PHILADELPHIA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
-
PHILADELPHIA, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
-
- In vivo data presented at ASH Annual Meeting demonstrated strong antitumor activity against human lymphoma cell lines with CNTY-101 - - Company announces plans for Phase 1 ELiPSE-1 trial of...
-
PHILADELPHIA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
-
Lead program, CNTY-101 in relapsed/refractory non-Hodgkin’s lymphoma, remains on track for IND filing in mid-2022 Pre-clinical data from CNTY-101 program and CAR-iT platform to be presented at the...
-
PHILADELPHIA, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
-
Collaboration enables Century to explore Outpace’s protein solutions for cell therapy to enhance functionality of iPSC platform Initial program to focus on hematological malignancies with option to...
-
PHILADELPHIA, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...